ARK Added Over $48M in Cerebras Last Week While Trimming ~$70M in Alibaba
Taylor Wilson
ARK Invest executed a clear directional rotation last week, adding ~$48 million in AI-chip maker Cerebras while cutting ~$70 million in Alibaba — a systematic shift from China tech and streaming into AI infrastructure and crypto finance.
Where did the biggest dollars go?
The single largest buy was Cerebras Systems (CBRS) — roughly 257,000 shares, worth about $48 million. This means → ARK sees AI-compute chips as its top-priority bet right now.
CoreWeave (CRWV) picked up ~76,000 shares, nearly $14 million. In plain terms = the chip maker and the compute-rental platform — ARK is buying both sides of the AI-infrastructure stack.
Tesla (TSLA) and Alphabet (GOOG) each added ~$8 million; Palantir (PLTR) added ~$17 million — the AI software layer got a top-up too.
Space and gaming were bought too — why?
ARK bought ~256,000 shares of SpaceX (SPCX) across multiple funds, adding ~$39 million in exposure. This reflects ARK treating space infrastructure as a long-term theme on the same tier as AI.
Roblox (RBLX) saw ~$23 million in additions; Amazon (AMZN) added ~41,000 shares.
In plain terms = the common label across this week's buys is "infrastructure" — compute, space, or platform, all pipes at the base layer.
How much went into crypto and fintech?
Coinbase (COIN) added over $11.1 million, Circle (CRCL) ~$6.2 million, Robinhood (HOOD) ~$4.6 million.
This means → ARK is betting that crypto evolves from trading into financial infrastructure — exchange, stablecoin issuer, and retail brokerage, all three lines at once.
In genomics, Recursion Pharmaceuticals (RXRX) was the week's largest buy by share count at ~1.76 million shares (~$6 million), but the dollar size is far smaller than the AI and crypto bets.
What got cut the hardest?
Roku (ROKU) was the week's biggest trim — ~731,000 shares sold, cutting exposure by ~$99 million. In plain terms = streaming no longer qualifies as "disruptive innovation" in ARK's eyes.
Alibaba (BABA) saw over 746,000 shares sold, a ~$70 million reduction; Baidu (BIDU) was trimmed lightly as well. This reflects a systematic drawdown of China-tech exposure.
Genomics also saw trims in Absci (ABSI), Strata Critical Medical (SRTA), and Twist Bioscience (TWST) — even within genomics, ARK is swapping names.
What does this rotation tell us?
The buy side clusters around AI compute + space + crypto finance; the sell side clusters around streaming + China tech — the directional signal is unmistakable.
This means → ARK's portfolio logic has shifted from "cast a wide net on disruption" to "concentrate on infrastructure pipes."
The key test: whether Cerebras and CoreWeave can deliver revenue growth in upcoming quarters — if earnings disappoint, this heavy positioning turns into a crowded trade at the top.
Content is for reference only, not financial advice.